ERBB2 and cancer: Despite the tremendous efforts made in developing cancer biomarkers and liquid biopsy for past decades, only a few (less than 25) cancer biomarkers have been approved by FDA for clinical practice1,2, such as Estrogen receptor (ER), Progesterone receptor (PR), HER-2/neu, CA-125, and PSA3.